Evidence map›Paper›PMID 39857736›Full record

ArticleBiomedicines2025

Proteomic Characterization of Liver Cancer Cells Treated with Clinical Targeted Drugs for Hepatocellular Carcinoma.

Hezhou Long, Jiafu Zhou, Changxia Zhou, Shuyu Xie, Jingling Wang, Minjia Tan, Junyu Xu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomedicines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hezhou LongSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Jiafu ZhouSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Changxia ZhouSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Shuyu XieSchool of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Jingling WangZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.
Minjia TanSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
Junyu XuSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.ORCID 0000-0002-1403-9200

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug combinationhepatocellular carcinomahepatocellular carcinoma-targeted drugsproteomicsS/T/Y phosphorylation

Identifiers

PMID39857736
PMCPMC11760458

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.